ABN AMRO Bank N.V. is a Dutch universal bank headquartered in Amsterdam. The group provides retail, private, and corporate banking services, with a primary focus on the Netherlands and selected international markets. Formed through mergers in the 1990s and restructured after the global financial crisis, ABN AMRO remains partly state-owned. Its activities include lending, deposits and payments, cash management, trade and export finance, capital markets access, M&A and corporate finance advisory, and risk management for interest rates, foreign exchange, and commodities.
For industrial clients—including the chemical sector—ABN AMRO offers working capital and investment financing, project and asset-backed solutions, supply-chain and receivables finance, and sustainability-linked instruments aligned with decarbonization targets. The bank also provides sector analysis and ESG expertise to support transition planning and risk assessment. Its corporate and institutional banking operations serve mid-sized to large enterprises and financial sponsors active across chemicals, energy, manufacturing, logistics, and related value chains.
Also known as ABN AMRO Bank.
chemXplore tracks 1 project involving ABN AMRO, of which one is active.
ABN AMRO's role on them: Investor / Financier.
1 new construction.
Contractors, licensors, and offtakers are recorded on this project For subscribers
Targeting: 2,5-Furandicarboxylic acid (1)
H1: revenues €4.7m, EBITDA -€18.8m, cash €23.9m; first FDCA batch produced; planned equity raise ≥€55m and proposed €20m facility; Worley contractual close‑out finalised.
First FDCA batch produced at Delfzijl; product qualification begins with aim for commercial sales by end of 2026.
Purification unit brought online, completing commissioning of all major process units; integrated start-up moves toward first FDCA production and end‑2026 commercial deliveries.
Oxidation unit commissioned; full start-up and first FDCA production targeted end‑2026; 22 offtakes and >150 kt reservations secured; pursuing €55m equity plus a €20m NOM loan.
Sale transfers Ray Technology patents for bio-based MEG/MPG (up to end‑2023). Seller refocuses on FDCA/PEF; €2.7M proceeds used to repay debt (€2.0M) and dismantle pilot (€0.7M).
Weld repairs completed with engineering partners. Commissioning continues: utilities and sugar dehydration online; oxidation and purification in final start-up. Commercial sales expected H2 2026
The plant will produce 100,000 tonnes of SAF annually, cutting GHG emissions by up to 90%. KLM is the main off-taker. Construction follows a seven-year development phase. Completion is due in 2028.
The plant will produce 100,000 tonnes of SAF annually, cutting GHG emissions by up to 90%. KLM is the main off-taker. Construction starts after securing non-recourse project financing.
By country, the most active first. active / all projects
